{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-032784","form_type":"8-K","ticker":"SNWV","cik":"0001417663","company_name":"SANUWAVE Health, Inc.","filed_at":"2024-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.984265+00:00","generated_at":"2026-05-31T22:00:45.590732+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sanuwave Health reports preliminary Q2 2024 revenue of $7.0-7.2M, highest quarterly revenue in history","bullets":["Preliminary Q2 2024 revenue $7.0M-$7.2M; up 50%-54% vs Q2 2023 and highest quarterly revenue ever.","UltraMist revenue grew >60% YoY and represents ~97% of total company revenue.","UltraMist applicator sales set all-time quarterly record, accounting for ~65% of total revenue.","Company expects to release full Q2 results in mid-August 2024; guidance at upper end of prior range."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-032784","json":"https://secwatch.observer/filing/0001140361-24-032784.json","markdown":"https://secwatch.observer/filing/0001140361-24-032784.md","text":"https://secwatch.observer/filing/0001140361-24-032784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417663/000114036124032784/0001140361-24-032784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417663/000114036124032784/ef20032251_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:00:45.590732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}